Fremanezumab 225 mg / 1.5 mL Suppliers & Bulk Manufacturers

Available Forms: Prefilled syringe

Available Strengths: 225 mg / 1.5 mL

Reference Brands: Ajovy (USA/EU)

Category: Neurology

Fremanezumab is a humanised monoclonal antibody that binds calcitonin gene-related peptide (CGRP), a neuropeptide central to the transmission of migraine pain. By neutralising CGRP it helps prevent migraine attacks. It is given by subcutaneous injection, either monthly or once every three months.

Product Description:

Fremanezumab is a humanised monoclonal antibody that binds calcitonin gene-related peptide itself, rather than its receptor — the distinction from erenumab. By neutralising circulating CGRP released from trigeminal nerve endings during migraine, it blocks the vasodilation and neurogenic inflammation CGRP drives. It is used for preventive treatment of episodic and chronic migraine in adults.

Its practical advantage is dosing flexibility: 225 mg monthly or 675 mg as three injections once every three months, which suits patients who prefer fewer injection days. In trials, benefit over placebo was seen within the first month, and a meaningful minority of patients had their monthly migraine days halved. It is generally well tolerated; injection site reactions are the most common adverse effect, and hypersensitivity reactions can be delayed. Constipation and blood pressure effects are less prominent than with the receptor antibody, though long-term cardiovascular data are still accumulating.

Sourcing notes. Originator biologic, on patent, with no biosimilar. Supplied as a prefilled syringe or autoinjector requiring refrigeration, so cold-chain integrity through distribution is part of the supply arrangement. Reimbursement generally restricts use to patients who have failed conventional preventives, which governs realistic volume. Treat enquiries as authorised-distributor supply rather than manufacture.